Biogen confirms Icahn ally is on board - South Florida Business Journal:

tatyanagepoji.blogspot.com
Shareholders were to elect four directors atthe meeting. Biogenb was pushing for the reelectiohn of all ofthe company’s existing directors, while Icahnj was angling to seat four new director. Accordingh to Biogen Idec, shareholders appead to have reelected current directors Robert Pangia andWilliam D. and elected Icahn ally Alexandedr Denner. Biogen Idec officialsz say the vote for the fourtj seat is too close to Biogen said the company will rely on the tabulationm of votes by its independent inspector of IVS Associates, before announcing the remaininhg director to serve on the board. Brucw R.
Ross, Biogen Idec’s said, “We welcome our new director to the boared and look forward to workinb together to build on our strong tracik record ofdelivering value. While we awaiy the outcome of the vote for the remaining we would like to express our gratitudr for the support ofour stockholders.” Icahn, in a filing with the Securitied and Exchange Commission, accused the company of preventing the votez cast from being counted. “If the board is successful, Richard a prominent scientistand physician, may be kept from legitimatelyy being elected to the board.
” Mulliga n is the Mallinckrodt Professor of Genetics at Harvarcd Medical School and directot of the Harvard Gene Therapy Initiative, accordintg to Harvard University’s Web site. Biogen said shareholderds rejected severalof Icahn’s other proposals, including moving the company’sz incorporation from Delaware to North Dakota, a move Icahn said woulr give more power to shareholders. Biogen officials said it appears that stockholdere also rejected a proposal by Icahn to limitt the size of the boarf to13 directors. Biogenm officials now have the power to enlarge the board as theysee fit.
Icahn is best knownj for unsuccessfully pushing BiogenIdec (Nasdaq: to sell itself in 2008. Last year, shareholderxs elected the company’s nominees over the slatr of investors put upby Icahn. Biogen Idec’ s (NASDAQ: BIIB) stock was trading at $53.17 in afternoonj trading Thursday, down from the previouxs day’s close of $53.43 a share.